tivoxavir marboxil

Tivoxavir marboxil is an investigational oral small molecule antiviral drug developed as a cap-dependent endonuclease (CEN) inhibitor. It is designed for single-dose administration to treat bird flu (notably H5N1 avian influenza) and seasonal influenza. Preclinical data in three animal species have shown that a single dose of tivoxavir marboxil demonstrates therapeutic effects against H5N1 bird flu. The drug targets the influenza virus by inhibiting the cap-dependent endonuclease, an essential enzyme for viral mRNA transcription, thereby blocking viral replication. Tivoxavir marboxil is being developed to address both pandemic threats like avian influenza and routine seasonal flu, with potential advantages in dosing simplicity and activity against resistant strains[8].

Brand names

TRX-100TRX100TRX 100

Other names

tivoxavir marboxil27-5116AV5124AV-5124AV 5124